218 related articles for article (PubMed ID: 15755793)
1. Discovery, clinical development, and therapeutic uses of bisphosphonates.
Licata AA
Ann Pharmacother; 2005 Apr; 39(4):668-77. PubMed ID: 15755793
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
3. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates: structure-activity relations from a clinical perspective.
Papapoulos SE
Medicina (B Aires); 1997; 57 Suppl 1():61-4. PubMed ID: 9567357
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
6. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
7. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
9. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Nancollas GH; Tang R; Phipps RJ; Henneman Z; Gulde S; Wu W; Mangood A; Russell RG; Ebetino FH
Bone; 2006 May; 38(5):617-27. PubMed ID: 16046206
[TBL] [Abstract][Full Text] [Related]
10. The use of bisphosphonates in cancer patients.
Wu S; Dahut WL; Gulley JL
Acta Oncol; 2007; 46(5):581-91. PubMed ID: 17562434
[TBL] [Abstract][Full Text] [Related]
11. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates: focus on inflammation and bone loss.
Iannitti T; Rosini S; Lodi D; Frediani B; Rottigni V; Palmieri B
Am J Ther; 2012 May; 19(3):228-46. PubMed ID: 22549638
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-induced osteonecrosis of the jaw.
Krueger CD; West PM; Sargent M; Lodolce AE; Pickard AS
Ann Pharmacother; 2007 Feb; 41(2):276-84. PubMed ID: 17299010
[TBL] [Abstract][Full Text] [Related]
14. Neridronic acid for the treatment of bone metabolic diseases.
Gatti D; Viapiana O; Idolazzi L; Fracassi E; Adami S
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1305-11. PubMed ID: 19761412
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
Rogers MJ; Xiong X; Brown RJ; Watts DJ; Russell RG; Bayless AV; Ebetino FH
Mol Pharmacol; 1995 Feb; 47(2):398-402. PubMed ID: 7870050
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology and therapeutic utility of bisphosphonates.
Lourwood DL
Pharmacotherapy; 1998; 18(4):779-89. PubMed ID: 9692651
[TBL] [Abstract][Full Text] [Related]
17. Antiresorptive dose-response relationships across three generations of bisphosphonates.
Sietsema WK; Ebetino FH; Salvagno AM; Bevan JA
Drugs Exp Clin Res; 1989; 15(9):389-96. PubMed ID: 2630251
[TBL] [Abstract][Full Text] [Related]
18. Who will benefit from antiresorptive treatment (bisphosphonates)?
Papapoulos SE
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):965-73. PubMed ID: 16301190
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
20. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.
Dunstan CR; Felsenberg D; Seibel MJ
Nat Clin Pract Oncol; 2007 Jan; 4(1):42-55. PubMed ID: 17183355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
